Interleukin-1 Beta Regulates Lysophosphatidic Acid-accelerated Skin Wound Healing

Delong Ge,Xiaoxiao Mou,Liying Liu,Yanwei Li,Hui Jiang,Jinjing Xie,Qingyan Guan,Gong Dai,Xiao Yang,Yuanyuan Gao,Xiaoyun Yang
DOI: https://doi.org/10.21203/rs.3.rs-114459/v1
2020-01-01
Abstract:Abstract Background: Interleukin 1 beta (IL-1β) is considered to be a mediator of infectious, inflammatory and autoimmune diseases, and the kinetics of its production is relevant to understanding the pathogenesis of these diseases. Lysophosphatidic acid (LPA), the structurally simplest bioactive phospholipid, is necessary for homeostasis in various physiological and pathophysiological processes and plays a pivotal role in wound healing. Skin trauma can not only weaken the barrier function, but also cause pain and infection. Chronic wounds are characterized by impaired healing and uncontrolled inflammation that damages the protection of the immune system. The aim of this study is to investigate whether inflammatory factor IL-1β has an effect on LPA in the wound healing model. Results: In this study, the kinetics of IL-1β gene expression was studied in vivo and in vitro with a wound healing model by quantitative real-time polymerase chain reaction (qRT-PCR) through LPA treatment. As a result, we found that LPA up-regulated inflammatory factor IL-1β in HaCaT cell and skin wound healing. The pro-inflammatory cytokines IL-1β mRNA had higher expression in LPA-treated mice group 3 days after the treatment. In vitro, after the treatment with LPA (20 μM) for 6, 12, and 24 hours, IL-1β mRNA expression increased by 61.16%, 129.39%, and 117.07%, respectively. Conclusion: These results strongly suggest that IL-1β may regulate LPA-accelerated skin wound healing. IL-1β has significant efficacy, and our observations are of interest to the development of drugs targeting LPA in skin therapy.
What problem does this paper attempt to address?